(thirdQuint)Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002.

 Only subjects previously enrolled in studies CTAP101-CL-3001 or CTAP101-CL-3002 are eligible to participate in this extension study.

 This is a phase 3, open-label study of CTAP101 Capsules, with and without add-on vitamin D hormone therapy.

.

 Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002@highlight

This extension study of subjects previously enrolled in studies CTAP101-CL-3001 or CTAP101-CL-3002 allows long term evaluation of the safety and efficacy of CTAP101 Capsules in reducing elevated intact parathyroid hormone (iPTH) and correcting vitamin D insufficiency in stage 3 or 4 chronic kidney disease patients.

